ANI Pharma rises after quarterly results beat estimates

Shares of drugmaker ANI Pharmaceuticals ANIP.O rise nearly 2% to $78.68 premarket

Co posts Q4 adjusted profit of $2.33 per share, compared to analysts' estimate of $2 per share, according to data compiled by LSEG

Posts Q4 revenue of $247.1 million vs. analysts' estimate of $231.5 million

Co says its key rare-disease product Cortrophin gel, used for severe inflammation and autoimmune conditions, generated $111.4 million in Q4 revenue

Says uptake of Cortrophin gel was helped by new patient starts and broader use across target conditions

Reaffirms FY26 revenue outlook of $1.06 billion to $1.12 billion, compared to average estimate of $982.5 million

ANIP shares had risen over 42% in 2025